Enzolytics Inc. (ENZC)
USD 0.0
(7.69%)
USD 0.0
(7.69%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 981.65 Thousand USD | 57.04% |
| 2022 | 625.08 Thousand USD | 167.12% |
| 2021 | -931.26 Thousand USD | -270.4% |
| 2020 | 546.51 Thousand USD | -20.89% |
| 2019 | 690.8 Thousand USD | 22.21% |
| 2018 | 565.28 Thousand USD | 35.24% |
| 2017 | 417.97 Thousand USD | 54.69% |
| 2016 | 270.2 Thousand USD | 4.53% |
| 2015 | 258.5 Thousand USD | 0.0% |
| 2010 | 288.51 Thousand USD | -32.71% |
| 2009 | 428.73 Thousand USD | 6.66% |
| 2008 | 401.94 Thousand USD | 16.29% |
| 2007 | 345.64 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 200.99 Million USD | 20112.62% |
| 2024 Q1 | 994.41 Thousand USD | 0.0% |
| 2023 Q2 | 1.41 Million USD | 38.29% |
| 2023 FY | 981.65 Thousand USD | 57.04% |
| 2023 Q3 | 1.17 Million USD | -16.62% |
| 2023 Q1 | 1.02 Million USD | 63.61% |
| 2022 Q2 | 841.64 Thousand USD | 809.73% |
| 2022 Q4 | 625.08 Thousand USD | -41.17% |
| 2022 FY | 625.08 Thousand USD | 167.12% |
| 2022 Q3 | 1.06 Million USD | 26.25% |
| 2022 Q1 | -118.58 Thousand USD | 0.0% |
| 2021 Q1 | -565.95 Thousand USD | -337.46% |
| 2021 FY | -931.26 Thousand USD | -270.4% |
| 2021 Q2 | -1.54 Million USD | -173.35% |
| 2021 Q3 | -1.15 Million USD | 25.53% |
| 2020 Q4 | -129.37 Thousand USD | 0.0% |
| 2020 FY | 546.51 Thousand USD | -20.89% |
| 2019 FY | 690.8 Thousand USD | 22.21% |
| 2018 FY | 565.28 Thousand USD | 35.24% |
| 2017 FY | 417.97 Thousand USD | 54.69% |
| 2016 FY | 270.2 Thousand USD | 4.53% |
| 2015 FY | 258.5 Thousand USD | 0.0% |
| 2011 Q1 | 298.94 Thousand USD | 3.62% |
| 2011 Q2 | 133.24 Thousand USD | -55.43% |
| 2010 Q4 | 288.51 Thousand USD | -69.31% |
| 2010 Q1 | 356.97 Thousand USD | -16.74% |
| 2010 FY | 288.51 Thousand USD | -32.71% |
| 2010 Q3 | 939.98 Thousand USD | -6.73% |
| 2010 Q2 | 1 Million USD | 182.33% |
| 2009 FY | 428.73 Thousand USD | 6.66% |
| 2009 Q4 | 428.73 Thousand USD | 25.94% |
| 2009 Q3 | 340.42 Thousand USD | -5.27% |
| 2009 Q2 | 359.35 Thousand USD | -6.78% |
| 2009 Q1 | 385.47 Thousand USD | -4.1% |
| 2008 Q1 | -1080.00 USD | -100.31% |
| 2008 Q4 | 401.94 Thousand USD | -5.07% |
| 2008 Q3 | 423.43 Thousand USD | 39306.57% |
| 2008 Q2 | -1080.00 USD | 0.0% |
| 2008 FY | 401.94 Thousand USD | 16.29% |
| 2007 Q4 | 345.64 Thousand USD | 32104.54% |
| 2007 Q3 | -1080.00 USD | 0.0% |
| 2007 FY | 345.64 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 75035.573% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 82.621% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 97.706% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 493.26% |
| Rebus Holdings, Inc. | 305 Thousand USD | -221.854% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 115.571% |
| Qrons Inc. | 351.42 Thousand USD | -179.334% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -57.73% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 97.74% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 4910.153% |
| Skye Bioscience, Inc. | -5.72 Million USD | 117.158% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 93.772% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 76.162% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -144.285% |
| SQZ Biotechnologies Company | -36.23 Million USD | 102.709% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 56.22% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -5.875% |
| Mesoblast Limited | 55.85 Million USD | 98.243% |
| Marizyme, Inc. | 18.56 Million USD | 94.713% |
| Genus plc | 190.6 Million USD | 99.485% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 56.094% |
| Pharming Group N.V. | 109.8 Million USD | 99.106% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -14.114% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 19.131% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -44.361% |
| ContraFect Corporation | -6.02 Million USD | 116.29% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -629.102% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 15.04% |
| IMV Inc. | 7.67 Million USD | 87.202% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 82.158% |
| MultiCell Technologies, Inc. | 90.04 USD | -1090144.336% |
| ONE Bio Corp. | 9.04 Million USD | 89.141% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 233.745% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 92.417% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 28.24% |
| Q BioMed Inc. | 4.06 Million USD | 75.821% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 96.787% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 2.586% |
| Biomind Labs Inc. | 711.4 Thousand USD | -37.989% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.379% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 50.902% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 92.335% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -172.902% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -602.166% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -4841.139% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 55.419% |
| GB Sciences, Inc. | 1.74 Million USD | 43.819% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 634.124% |
| HST Global, Inc. | 96.79 Thousand USD | -914.181% |
| CSL Limited | 10.52 Billion USD | 99.991% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -376.031% |
| Halberd Corporation | 144.72 Thousand USD | -578.309% |
| Agentix Corp. | 37.63 Thousand USD | -2508.636% |
| Resverlogix Corp. | 6.45 Million USD | 84.783% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 245.843% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.048% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 102.088% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 86.117% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 63.758% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 111.105% |
| AVAX Technologies, Inc. | -5.9 Million USD | 116.629% |
| Zenith Capital Corp. | 10.06 Thousand USD | -9654.134% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.092% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -389.77% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 58.858% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -496.719% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 5458.969% |
| Kadimastem Ltd | -253.1 Thousand USD | 487.85% |
| Helix BioMedix, Inc. | -2.57 Million USD | 138.196% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 95.159% |
| BioStem Technologies, Inc. | 4.47 Million USD | 78.049% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -387.77% |
| LadRx Corporation | -2.03 Million USD | 148.204% |
| Cell Source, Inc. | 9.23 Million USD | 89.367% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -54.551% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -54.551% |
| NovAccess Global Inc. | 2.17 Million USD | 54.938% |
| Affymax, Inc. | -5.59 Million USD | 117.539% |
| Itoco Inc. | 228.3 Thousand USD | -329.976% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -621.864% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 80.197% |
| Mobile Lads Corp. | 484.23 Thousand USD | -102.724% |
| CytoDyn Inc. | 20.26 Million USD | 95.155% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 151824.266% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 10691.498% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 87.261% |
| SYBLEU INC | 473.71 Thousand USD | -107.225% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 77.975% |
| International Stem Cell Corporation | 2.59 Million USD | 62.098% |
| Bioxytran, Inc. | 1.89 Million USD | 48.304% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1472.839% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 54.988% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 71.414% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 88.523% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -27.058% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 178.532% |
| Neutra Corp. | 52.18 Thousand USD | -1781.036% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 139.44% |
| PureTech Health plc | -167.19 Million USD | 100.587% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 500.826% |
| IXICO plc | -4.44 Million USD | 122.087% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 92.574% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 98.21% |
| CSL Limited | 10.52 Billion USD | 99.991% |
| Cellectis S.A. | -43.81 Million USD | 102.24% |